Oaktree Acquisition Corp. III Life Sciences (OACC) Financial Ratios
1 years of historical data (2024–2024) · Financial Services · Shell Companies
EV/EBITDA
9999.00
↓-100% vs avg
5yr avg: 243499149.28
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
1.39
+7% vs avg
5yr avg: 1.31
30Y Low1.3·High1.3
ROE
0.0%
+0% vs avg
5yr avg: 0.0%
30Y Low0%·High0%
Debt/EBITDA
19320.26
+0% vs avg
5yr avg: 19320.26
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OACC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Oaktree Acquisition Corp. III Life Sciences trades at 195.8x earnings, 7% above its 5-year average of 183.8x, sitting at the 100th percentile of its historical range. Compared to the Financial Services sector median P/E of 13.1x, the stock trades at a premium of 1389%.
| Metric | TTM | FY 2024 |
|---|---|---|
| Market Cap | $261M | $245M |
| Enterprise Value | $259M | $243M |
| P/E Ratio → | 195.76 | 183.76 |
| P/S Ratio | — | — |
| P/B Ratio | 1.39 | 1.31 |
| P/FCF | — | — |
| P/OCF | — | — |
P/E links to full P/E history page with 30-year chart
OACC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Oaktree Acquisition Corp. III Life Sciences's enterprise value stands at 9999.0x EBITDA, 100% below its 5-year average of 243499149.3x. The Financial Services sector median is 11.5x, placing the stock at a 87091% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 |
|---|---|---|
| EV / Revenue | — | — |
| EV / EBITDA | 9999.00 | 243499149.28 |
| EV / EBIT | — | — |
| EV / FCF | — | — |
OACC Profitability
Margins and return-on-capital ratios measuring operating efficiency
ROE of 0.0% is modest, trailing the sector median of 9.4%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Profit Margin | — | — |
Return on Capital
| Metric | TTM | FY 2024 |
|---|---|---|
| ROE | 0.0% | 0.0% |
| ROA | 0.0% | 0.0% |
| ROIC | — | — |
| ROCE | -0.0% | -0.0% |
OACC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Oaktree Acquisition Corp. III Life Sciences carries a Debt/EBITDA ratio of 19320.3x, which is highly leveraged (465666% above the sector average of 4.1x). The company holds a net cash position — cash of $1M exceeds total debt of $11824, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 |
|---|---|---|
| Debt / Equity | 0.00 | 0.00 |
| Debt / EBITDA | 19320.26 | 19320.26 |
| Net Debt / Equity | — | -0.01 |
| Net Debt / EBITDA | -999999.00 | -1345220.00 |
| Debt / FCF | — | — |
| Interest Coverage | — | — |
Net cash position: cash ($1M) exceeds total debt ($11824)
OACC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Oaktree Acquisition Corp. III Life Sciences's current ratio of 2.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2024 |
|---|---|---|
| Current Ratio | 2.14 | 2.14 |
| Quick Ratio | 2.14 | 2.14 |
| Cash Ratio | 1.87 | 1.87 |
| Asset Turnover | — | — |
| Inventory Turnover | — | — |
| Days Sales Outstanding | — | — |
OACC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Oaktree Acquisition Corp. III Life Sciences does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Dividend Yield | — | — |
| Payout Ratio | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 |
|---|---|---|
| Earnings Yield | 0.5% | 0.5% |
| FCF Yield | — | — |
| Buyback Yield | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% |
| Shares Outstanding | — | $25M |
Peer Comparison
Compare OACC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OACCYou | $261M | 195.8 | 9999.0 | — | — | — | 0.0% | — | 19320.3 |
 RLAY | $2B | -7.8 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 BCTX | $5M | -0.0 | — | — | — | — | -363.0% | -1263.2% | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 BFLY | $1B | -13.7 | — | — | 46.9% | -88.5% | -42.2% | -76.8% | — |
 GH | $12B | -27.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
| Financial Services Median | — | 13.1 | 11.5 | 10.6 | 63.6% | 21.6% | 9.4% | 5.7% | 4.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 1 years · Updated daily
See OACC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OACC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OACC vs RLAY
Side-by-side business, growth, and profitability comparison vs Relay Therapeutics, Inc..
Start ComparisonOACC — Frequently Asked Questions
Quick answers to the most common questions about buying OACC stock.
What is Oaktree Acquisition Corp. III Life Sciences's P/E ratio?
Oaktree Acquisition Corp. III Life Sciences's current P/E ratio is 195.8x. The historical average is 183.8x. This places it at the 100th percentile of its historical range.
What is Oaktree Acquisition Corp. III Life Sciences's EV/EBITDA?
Oaktree Acquisition Corp. III Life Sciences's current EV/EBITDA is 9999.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Oaktree Acquisition Corp. III Life Sciences's ROE?
Oaktree Acquisition Corp. III Life Sciences's return on equity (ROE) is 0.0%. The historical average is 0.0%.
Is OACC stock overvalued?
Based on historical data, Oaktree Acquisition Corp. III Life Sciences is trading at a P/E of 195.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
How much debt does Oaktree Acquisition Corp. III Life Sciences have?
Oaktree Acquisition Corp. III Life Sciences's Debt/EBITDA ratio is 19320.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.